These findings illustrate that nxhl can regulate angiogenesis via the novel nxhl–NCL–VE-PTP axis, and thus the results provide a new therapeutic target for modulation of angiogenesis, especially for cancer treatment. This evidence concerns the gene NUCLEOLIN and cancer.